Table 2.

The relationship between SLC30A family genes and OS in different gender of GC patients (Kaplan–Meier Plotter).

	Gender	Cases	HR (95% CI)	P-value
SLC30A1	Male	349	0.54 (0.39–0.76)	0.0004*
	Female	187	0.52 (0.34–0.8)	0.0026*
SLC30A2	Male	349	2 (1.37–2.91)	0.0002*
	Female	187	1.95 (1.11–3.4)	0.0170*
SLC30A3	Male	349	1.67 (1.34–2.07)	2.8e−06*
	Female	187	1.95 (1.36–2.8)	0.0002*
SLC30A4	Male	349	1.52 (1.12–2.06)	0.0065*
	Female	187	1.68 (1.1–2.59)	0.0161*
SLC30A5	Male	349	0.55 (0.4–0.74)	6.6e−05*
	Female	187	0.58 (0.36–0.91)	0.0171*
SLC30A6	Male	349	0.5 (0.37–0.67)	2.7e−06*
	Female	187	0.59 (0.36–0.97)	0.0370*
SLC30A7	Male	349	0.45 (0.33–0.61)	1.3e−07*
	Female	187	0.64 (0.42–0.99)	0.0431*
SLC30A8	Male	349	1.37 (1.02–1.84)	0.0370*
	Female	187	2.49 (1.6–3.87)	2.8e−05*
SLC30A9	Male	349	0.47 (0.38–0.59)	3.7e−11*
	Female	187	0.54 (0.37–0.78)	0.0010*
SLC30A10	Male	349	1.73 (1.32–2.25)	4.8e−05*
	Female	187	1.35 (0.95–1.92)	0.0930*

a: The P-value was set at 0.05 and the * indicate that the results are statistically significant.

b: SLC30, The solute carriers’ families 30; OS, overall survival; HR, hazard ratio; CI, confidence interval.